$8.38
4.91% yesterday
Nasdaq, May 20, 09:35 pm CET
ISIN
VGG7185A1286
Symbol
PRTG
Sector
Industry

Portage Biotech Inc Stock price

$8.33
-0.76 8.36% 1M
+3.76 82.28% 6M
+3.16 61.12% YTD
+2.82 51.12% 1Y
-154.47 94.88% 3Y
-277.07 97.08% 5Y
-211.87 96.22% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.34 4.26%
ISIN
VGG7185A1286
Symbol
PRTG
Sector
Industry

Key metrics

Market capitalization $5.55m
Enterprise Value $3.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 6.65
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-11.76m
Free Cash Flow (TTM) Free Cash Flow $-9.80m
Cash position $1.76m
EPS (TTM) EPS $-65.69
P/E forward negative
Short interest 8.78%
Show more

Is Portage Biotech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Portage Biotech Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Portage Biotech Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Portage Biotech Inc:

Hold
100%

Financial data from Portage Biotech Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
33% 33%
-
-0.04 -0.04
33% 33%
-
- Selling and Administrative Expenses 4.97 4.97
30% 30%
-
- Research and Development Expense 6.70 6.70
47% 47%
-
-12 -12
41% 41%
-
- Depreciation and Amortization 0.04 0.04
33% 33%
-
EBIT (Operating Income) EBIT -12 -12
41% 41%
-
Net Profit -67 -67
40% 40%
-

In millions USD.

Don't miss a Thing! We will send you all news about Portage Biotech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Portage Biotech Inc Stock News

Neutral
GlobeNewsWire
23 days ago
DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor.
Positive
Market Watch
about 2 months ago
Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.
Neutral
GlobeNewsWire
2 months ago
Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in Patients Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in Patients
More Portage Biotech Inc News

Company Profile

Portage Biotech, Inc. is a biotechnology company, which enables research and development to produce clinical programs and maximize potential returns. Its portfolio includes subsidiary companies, whose products or technologies have established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. The firm provides funding, strategic business and clinical counsel, and shared services to treat different types of cancers. The company was founded by Gregory H. Bailey in 1973 and is headquartered in Road Town, British Virgin Islands.

Head office Virgin Islands, British
CEO Alexander Pickett
Employees 7
Founded 1973
Website www.portagebiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today